Payload Information

General Information of This Payload
Payload ID
PAY0LSGQO
Name
Curcumin
Synonyms
Curcumin; 458-37-7; Diferuloylmethane; Natural yellow 3; Indian saffron; Kacha haldi; Curcuma; Gelbwurz; Haldar; Curcumin I; Souchet; Haidr; Halad; Halud; Yellow Ginger; Terra Merita; (1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione; Safran d'Inde; Yo-Kin; C.I. Natural Yellow 3; Hydrastis; Yellow puccoon; Golden seal; Diferaloylmethane; Curcumine; Tumeric yellow; CI Natural Yellow 3; Kurkumin [Czech]; Kurkumin; C.I. 75300; 8024-37-1; Zlut prirodni 3; curouma; Jianghuangsu; Zlut prirodni 3 [Czech]; Cucurmin; Curcumin (synthetic); kachs haldi; NanoCurc; E 100; safra d'inde; Tumeric oleoresin; 1,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione; 94875-80-6; CI 75300; NSC32982; NSC 32982; 1,7-Bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione; CCRIS 3257; CHEBI:3962; Curcurmin; Lipocurc; Tumeric; Kurkum; Ukon; HSDB 4334; 1,5-Di(vanillyliden)acetylaceton; NCI-C61325; 1,5-Divanillyliden-2,4-pentandion; EINECS 207-280-5; UNII-IT942ZTH98; MFCD00008365; NSC-32982; Curcumin e100; Ukon (dye); 98% curcurmin); NSC 687842; trans,trans-Curcumin; BRN 2306965; FEMA No. 3085; FEMA No. 3086; CCRIS 5804; IT942ZTH98; 1,9-Bis(4-hydroxy-3-methoxyphenyl)-2,7-nonadiene-4,6-dione; E 100 (Dye); MLS000069631; C Yellow 15; DTXSID8031077; (1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione; 1,6-Heptadiene-3,5-dione, 1,7-bis(4-hydroxy-3-methoxyphenyl)-, (E,E)-; C21H20O6; CHEMBL140; Curcuma longa l. oleoresin; NSC-687842; 1,6-Heptadiene-3,5-dione, 1,7-bis(4-hydroxy-3-methoxyphenyl)-; (E,E)-1,7-bis(4-Hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione; SMR000058237; 1,6-Heptadiene-3,5-dione, 1,7-bis(4-hydroxy-3-methoxyphenyl)-, (1E,6E)-; DTXCID901421; E-100; INS NO. 100(I); INS-100(I); 4-08-00-03697 (Beilstein Handbook Reference); NSC687842; NCGC00017159-05; 2,7-Nonadiene-4,6-dione, 1,9-bis(4-hydroxy-3-methoxyphenyl)-; CURCUMIN (MART.); CURCUMIN [MART.]; (1E,6E)-1,7-bis(4-hydroxy-3-methoxy-phenyl)hepta-1,6-diene-3,5-dione; (1E,6E)-1,7-bis[4-hydroxy-3-(methyloxy)phenyl]hepta-1,6-diene-3,5-dione; CU-01000001305-2; CURCUMIN (SEE ALSO TUMERIC, OLEORESIN (10105-J)); 1,7-BIS-(4-HYDROXY-3-METHOXYPHENYL)-HEPTA-1,6-DIENE-3,5-DIONE; PREVENTION 4 (CURCUMIN) (SEE ALSO TUMERIC, OLEORESIN (10105-J)); CAS-458-37-7; Phytosome, Curcumin; SR-01000000149; Curcumin W; Curcumin,(S); Curcumin (Natural); (E/Z)-Curcumin; Curcumin (6CI); trans trans-Curcumin; Colorant E 100; San-Ei Curcumine AL; starbld0017234; CURCUMIN [HSDB]; CURCUMIN [INCI]; CURCUMIN [MI]; Opera_ID_1627; San-Ei Gen Curcumine AL; CURCUMIN [USP-RS]; CURCUMIN [WHO-DD]; D07SDQ; D0H8LC; SCHEMBL8440; SCHEMBL8441; Curcumin, analytical standard; MLS001148449; BIDD:ER0479; UNII-856YO1Z64F; cid_969516; GTPL7000; SCHEMBL13521974; SCHEMBL23884885; SCHEMBL23884886; SCHEMBL23884892; SCHEMBL23884893; BDBM29532; cid_5281767; cMAP_000052; CI 75300 [INCI]; HMS2233K04; HMS3649K06; 91884-86-5; AMY33436; BCP04695; Tox21_110803; Tox21_111505; Tox21_201116; BBL027711; BDBM50067040; BDBM50140172; CCG-36020; CCG-36107; LS-125; STL371943; AKOS001305497; BCP9000557; DB11672; LS-2189; NCGC00017159-04; NCGC00017159-06; NCGC00017159-07; NCGC00017159-09; NCGC00017159-10; NCGC00017159-11; NCGC00017159-12; NCGC00023332-03; NCGC00023332-04; NCGC00023332-05; NCGC00258668-01; AC-24238; AS-72202; BP-25396; CURCUMIN (CONSTITUENT OF TURMERIC); BCP0726000035; WLN: 1OR BQ E1U1V1V1U1R DQ CO1; C-230; C2302; CS-0149275; 1,3-Di(3-methoxy-4-hydroxystyryl)propanedial; EN300-21494; F21478; K00009; Curcumin, Curcuma longa L. - CAS 458-37-7; A826902; Curcumin, primary pharmaceutical reference standard; Q312266; 1,5-dione, 1,7-bis(4-hydroxy-3-methoxyphenyl)-; SR-01000000149-2; SR-01000000149-5; BRD-K07572174-001-02-2; BRD-K07572174-001-19-6; BRD-K07572174-001-22-0; Z104500108; Curcumin, >=94% (curcuminoid content), >=80% (Curcumin); 1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadien-3,5-dione; 1,7-bis(4-hydroxy-3-methoxyphenyl)1,6-heptadiene-3,5-dione; Curcumin, matrix substance for MALDI-MS, >=99.5% (HPLC); Curcumin, United States Pharmacopeia (USP) Reference Standard; (E)-1 7-Bis(4-hydroxy-3-methoxyphenyl)-1 6-heptadiene-3 5-dione; 1,7-BIS(4-HYDROXYMETHOXYPHENYL)-1,6-HEPTADIENE-3,5-DIONE; 1,7-Bis-(4-hydroxy-3-methoxy-phenyl)-hepta-1,6-diene-3,5-dione; 1,7-bis-(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione; '(1E,6E)-1,7-bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione'; ((E,E)-1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione); (1E 6E)-1 7-Bis(4-hydroxy-3-methoxyphenyl)-1 6-heptadiene-3 5-dione; (1E,6E)-1,7-bis(3-methoxy-4-oxidanyl-phenyl)hepta-1,6-diene-3,5-dione; (1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione #; (1E,6E)-1,7-bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione.; (1E,6E)-1,7-Bis-(4-hydroxy-3-methoxy-phenyl)-hepta-1,6-diene-3,5-dione; (1Z,6E)-1,7-Bis-(4-hydroxy-3-methoxy-phenyl)-hepta-1,6-diene-3,5-dione; (E E)-1 7-Bis(4-hydroxy-3-methoxyphenyl)-1 6-heptadiene-3 5-dione; 1,6-heptadieno-3,5-diona, 1,7-bis(4-hidroxi-3-metoxifenil)-, (1e,6e)-; 1,7-Bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione, (E,E)-; 5-hydroxy-1,7-bis(4-hydroxy-3-methoxyphenyl)-1,4,6-heptatrien-3-one; 5-Hydroxy-1,7-bis-(4-hydroxy-3-methoxy-phenyl)-hepta-1,4,6-trien-3-one; Curcumin; 1,7-Bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione; (1E,4Z,6E)-5-Hydroxy-1,7-bis-(4-hydroxy-3-methoxy-phenyl)-hepta-1,4,6-trien-3-one; 1 6-Heptadiene-3 5-dione 1 7-bis(4-hydroxy-3-methoxyphenyl)-(E E)-(8CI); 1, 7- bis(4- hydroxy- 3- methoxyphenyl)hepta- 1, 6- diene- 3, 5- dione
   Click to Show/Hide
Target(s) Arylamine N-acetyltransferase 2 (NAT2)
 Target Info 
Structure
Formula
C21H20O6
Isosmiles
COC1=C(C=CC(=C1)/C=C/C(=O)CC(=O)/C=C/C2=CC(=C(C=C2)O)OC)O
PubChem CID
969516
InChI
InChI=1S/C21H20O6/c1-26-20-11-14(5-9-18(20)24)3-7-16(22)13-17(23)8-4-15-6-10-19(25)21(12-15)27-2/h3-12,24-25H,13H2,1-2H3/b7-3+,8-4+
InChIKey
VFLDPWHFBUODDF-FCXRPNKRSA-N
IUPAC Name
(1E,6E)-1,7-bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione
Pharmaceutical Properties
Molecule Weight
368.4
Polar area
93.1
Complexity
507
xlogp Value
3.2
Heavy Count
27
Rot Bonds
8
Hbond acc
6
Hbond Donor
2
The activity data of This Payload
Standard Type Value Units Cell line Disease Model Cell line ID Reference
Half Maximal Cell Growth Inhibitory Concentration (GI50) 12.7 ug/mL
COLO 205 cells
Colon adenocarcinoma
CVCL_0218 
[1]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 13.8 ug/mL
PC-3 cells
Prostate carcinoma
CVCL_0035 
[1]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 14.3 ug/mL
22RV1 cells
Prostate carcinoma
CVCL_1045 
[1]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 4.3 ug/mL
LoVo cells
Colon adenocarcinoma
CVCL_0399 
[1]
Half Maximal Inhibitory Concentration (IC50) 6.278 ug/mL
HCT-8 cells
Ileocecal adenocarcinoma
CVCL_2478 
[2]
Half Maximal Inhibitory Concentration (IC50) 6.496 ug/mL
Bel-7402 cells
Hepatoma
CVCL_5492 
[2]
Half Maximal Inhibitory Concentration (IC50) 6.52 ug/mL
A2780 cells
Ovarian endometrioid adenocarcinoma
CVCL_0134 
[2]
Half Maximal Inhibitory Concentration (IC50) 6.521 ug/mL
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[2]
Half Maximal Inhibitory Concentration (IC50) 6.806 ug/mL
BGC-823 cells
Stomach adenocarcinoma
CVCL_3360 
[2]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 7.2 ug/mL
CCD-18Co cells
Normal
CVCL_2379 
[1]
Half Maximal Inhibitory Concentration (IC50) 7.7 ug/mL
HEK293 cells
Normal
CVCL_0045 
[1]
Half Maximal Inhibitory Concentration (IC50) >10000 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[3]
Half Maximal Inhibitory Concentration (IC50) 10000 nM
Hep-G2 cells
Hepatoblastoma
CVCL_0027 
[4]
Half Maximal Inhibitory Concentration (IC50) 10000 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[5]
Half Maximal Inhibitory Concentration (IC50) 10000 nM
HT-1080 cells (FAP expression)
Fibrosarcoma
CVCL_0317 
[6]
Half Maximal Inhibitory Concentration (IC50) 10000 nM
Hep 3B2.1-7 cells
Childhood hepatocellular carcinoma
CVCL_0326 
[6]
Half Maximal Inhibitory Concentration (IC50) 10000 nM
SW480 cells
Colon adenocarcinoma
CVCL_0546 
[5]
Half Maximal Inhibitory Concentration (IC50) 10000 nM
T98G cells
Glioblastoma
CVCL_0556 
[7]
Half Maximal Inhibitory Concentration (IC50) >10000 nM
MDA-MB-231 cells (5T4 overexpression)
Breast adenocarcinoma
CVCL_0062 
[3]
Half Maximal Inhibitory Concentration (IC50) >100000 nM
A-431 cells
Skin squamous cell carcinoma
CVCL_0037 
[8]
Half Maximal Inhibitory Concentration (IC50) >100000 nM
RAW264.7 cells
Monocytic-macrophage leukemia
CVCL_0493 
[9]
Half Maximal Inhibitory Concentration (IC50) 100000 nM
QG-56 cells
Lung squamous cell carcinoma
CVCL_6943 
[10]
Half Maximal Inhibitory Concentration (IC50) 100000 nM
QG-56 cells
Lung squamous cell carcinoma
CVCL_6943 
[11]
Half Maximal Inhibitory Concentration (IC50) 10300 nM
Caco-2 cells
Colon adenocarcinoma
CVCL_0025 
[12]
Half Maximal Inhibitory Concentration (IC50) 10500 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[13]
Half Maximal Inhibitory Concentration (IC50) 105110 nM
CCD-841CoN cells
Normal
CVCL_2871 
[6]
Half Maximal Inhibitory Concentration (IC50) 107 nM
H4 cells
Neuroglioma
CVCL_1239 
[14]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 10889.3 nM
Hs 578T cells
Invasive breast carcinoma
CVCL_0332 
[15]
Half Maximal Inhibitory Concentration (IC50) 10910 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[3]
Half Maximal Inhibitory Concentration (IC50) 10970 nM
Vero cells
Normal
CVCL_0059 
[16]
Half Maximal Inhibitory Concentration (IC50) 11000 nM
T-47D cells
Invasive breast carcinoma
CVCL_0553 
[6]
Half Maximal Inhibitory Concentration (IC50) 11000 nM
BT474-M1 cells
Invasive breast carcinoma
CVCL_0179 
[6]
Half Maximal Inhibitory Concentration (IC50) 11000 nM
HSC-3 cells
Oral squamous cell carcinoma
CVCL_1288 
[17]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 11324 nM
UO-31 cells
Renal carcinoma
CVCL_1911 
[15]
Half Maximal Inhibitory Concentration (IC50) 11450 nM
MDA-MB-231 cells (5T4 overexpression)
Breast adenocarcinoma
CVCL_0062 
[17]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 11508 nM
UACC-257 cells
Melanoma
CVCL_1779 
[15]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 11912.42 nM
Caki-1 cells
Clear cell renal cell carcinoma
CVCL_0234 
[15]
Half Maximal Inhibitory Concentration (IC50) 12000 nM
MDA-MB-231 cells (5T4 overexpression)
Breast adenocarcinoma
CVCL_0062 
[18]
Half Maximal Inhibitory Concentration (IC50) 12110 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[19]
Half Maximal Inhibitory Concentration (IC50) 12220 nM
PC-3 cells
Prostate carcinoma
CVCL_0035 
[20]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 12387.97 nM
ACHN cells
Renal adenocarcinoma
CVCL_1067 
[15]
Half Maximal Inhibitory Concentration (IC50) 12520 nM
SW620 cells
Colon adenocarcinoma
CVCL_0547 
[21]
Half Maximal Inhibitory Concentration (IC50) 12570 nM
SMMC-7721 cells
Hepatocellular carcinoma
CVCL_0534 
[17]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 12793.81 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[15]
Half Maximal Inhibitory Concentration (IC50) 13000 nM
HaCaT cells
Normal
CVCL_0038 
[6]
Half Maximal Inhibitory Concentration (IC50) 13100 nM
HT-1080 cells (FAP expression)
Fibrosarcoma
CVCL_0317 
[22]
Half Maximal Inhibitory Concentration (IC50) 132370 nM
HT-29 cells
Colon adenocarcinoma
CVCL_0320 
[6]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 13458.6 nM
COLO 205 cells
Colon adenocarcinoma
CVCL_0218 
[15]
Half Maximal Inhibitory Concentration (IC50) 13610 nM
LNCaP cells
Prostate carcinoma
CVCL_0395 
[19]
Half Maximal Inhibitory Concentration (IC50) 13610 nM
LNCaP cells
Prostate carcinoma
CVCL_0395 
[23]
Half Maximal Inhibitory Concentration (IC50) 13610 nM
LNCaP cells
Prostate carcinoma
CVCL_0395 
[24]
Half Maximal Inhibitory Concentration (IC50) 13610 nM
LNCaP cells
Prostate carcinoma
CVCL_0395 
[25]
Half Maximal Inhibitory Concentration (IC50) 13610 nM
LNCaP cells
Prostate carcinoma
CVCL_0395 
[26]
Half Maximal Inhibitory Concentration (IC50) 13770 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[27]
Half Maximal Inhibitory Concentration (IC50) 13780 nM
Hep-G2 cells
Hepatoblastoma
CVCL_0027 
[28]
Half Maximal Inhibitory Concentration (IC50) 1400 nM
NCI-H1975 cells
Lung adenocarcinoma
CVCL_1511 
[29]
Half Maximal Inhibitory Concentration (IC50) 14000 nM
SW620 cells
Colon adenocarcinoma
CVCL_0547 
[22]
Half Maximal Inhibitory Concentration (IC50) 14000 nM
HT-29 cells
Colon adenocarcinoma
CVCL_0320 
[18]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 14028.14 nM
Malme-3M cells
Melanoma
CVCL_1438 
[15]
Half Maximal Inhibitory Concentration (IC50) 14030 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[17]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 14157.94 nM
TK-10 cells
Renal carcinoma
CVCL_1773 
[15]
Half Maximal Inhibitory Concentration (IC50) 1420 nM
BV-2 cells
Normal
CVCL_0182 
[30]
Half Maximal Inhibitory Concentration (IC50) 145500 nM
DLD-1 cells
Colon adenocarcinoma
CVCL_0248 
[6]
Half Maximal Inhibitory Concentration (IC50) 14700 nM
RAW264.7 cells
Monocytic-macrophage leukemia
CVCL_0493 
[9]
Half Maximal Inhibitory Concentration (IC50) 15000 nM
LN-229 cells
Glioblastoma
CVCL_0393 
[18]
Half Maximal Inhibitory Concentration (IC50) 15000 nM
NCI-H460 cells
Lung large cell carcinoma
CVCL_0459 
[18]
Half Maximal Inhibitory Concentration (IC50) 15000 nM
SW480 cells
Colon adenocarcinoma
CVCL_0546 
[17]
Half Maximal Inhibitory Concentration (IC50) 15060 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[31]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 15135.61 nM
EKVX cells
Non-small cell lung carcinoma
CVCL_1195 
[15]
Half Maximal Inhibitory Concentration (IC50) 15200 nM
HEK-293T cells
Normal
CVCL_0063 
[32]
Half Maximal Inhibitory Concentration (IC50) 15260 nM
U-251MG cells
Astrocytoma
CVCL_0021 
[17]
Half Maximal Inhibitory Concentration (IC50) 15620 nM
RWPE-1 cells
Normal
CVCL_3791 
[17]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 15667.51 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[15]
Half Maximal Inhibitory Concentration (IC50) 15810 nM
MDA-MB-231 cells (5T4 overexpression)
Breast adenocarcinoma
CVCL_0062 
[20]
Half Maximal Inhibitory Concentration (IC50) 15950 nM
RAW264.7 cells
Monocytic-macrophage leukemia
CVCL_0493 
[33]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 15958.79 nM
A498 cells
Renal carcinoma
CVCL_1056 
[15]
Half Maximal Inhibitory Concentration (IC50) 16000 nM
U-87MG ATCC cells
Glioblastoma
CVCL_0022 
[18]
Half Maximal Inhibitory Concentration (IC50) 16000 nM
KM12 cells
Colon adenocarcinoma
CVCL_1331 
[6]
Half Maximal Inhibitory Concentration (IC50) 16010 nM
Hep-G2 cells
Hepatoblastoma
CVCL_0027 
[34]
Half Maximal Inhibitory Concentration (IC50) 16100 nM
SH-SY5Y cells
Bone marrow neuroblastoma
CVCL_0019 
[35]
Half Maximal Inhibitory Concentration (IC50) 16230 nM
MDA-MB-231 cells (5T4 overexpression)
Breast adenocarcinoma
CVCL_0062 
[27]
Half Maximal Inhibitory Concentration (IC50) 1630 nM
MCF7-VP cells
Breast carcinoma
CVCL_5I65 
[36]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 16481.62 nM
SK-MEL-2 cells (MEK inhibitor-resistant)
Melanoma
CVCL_0069 
[15]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 16557.7 nM
OVCAR-5 cells
Ovarian serous adenocarcinoma
CVCL_1628 
[15]
Half Maximal Inhibitory Concentration (IC50) 16680 nM
SMMC-7721 cells
Hepatocellular carcinoma
CVCL_0534 
[37]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 16710.91 nM
NCI-H322M cells
Minimally invasive lung adenocarcinoma
CVCL_1557 
[15]
Half Maximal Inhibitory Concentration (IC50) 17100 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[17]
Half Maximal Inhibitory Concentration (IC50) 17110 nM
NCI-H460 cells
Lung large cell carcinoma
CVCL_0459 
[38]
Half Maximal Inhibitory Concentration (IC50) 17140 nM
NCI-H460 cells
Lung large cell carcinoma
CVCL_0459 
[39]
Half Maximal Inhibitory Concentration (IC50) 17300 nM
Hep-G2 cells
Hepatoblastoma
CVCL_0027 
[40]
Half Maximal Inhibitory Concentration (IC50) 17370 nM
Hep-G2 cells
Hepatoblastoma
CVCL_0027 
[37]
Half Maximal Inhibitory Concentration (IC50) 17500 nM
BGC-823 cells
Stomach adenocarcinoma
CVCL_3360 
[17]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 17823.79 nM
MDA-MB-231 cells (5T4 overexpression)
Breast adenocarcinoma
CVCL_0062 
[15]
Half Maximal Inhibitory Concentration (IC50) 17870 nM
Vero cells
Normal
CVCL_0059 
[16]
Half Maximal Inhibitory Concentration (IC50) 17900 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[22]
Half Maximal Inhibitory Concentration (IC50) 17940 nM
SW480 cells
Colon adenocarcinoma
CVCL_0546 
[6]
Half Maximal Inhibitory Concentration (IC50) 18000 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[18]
Half Maximal Inhibitory Concentration (IC50) 18000 nM
COLO 201 cells
Colon adenocarcinoma
CVCL_1987 
[18]
Half Maximal Inhibitory Concentration (IC50) 18250 nM
BxPC-3 CDX model cells
Pancreatic ductal adenocarcinoma
CVCL_0186 
[17]
Half Maximal Inhibitory Concentration (IC50) 18400 nM
U-87MG ATCC cells
Glioblastoma
CVCL_0022 
[41]
Half Maximal Inhibitory Concentration (IC50) 18650 nM
PC-3 cells
Prostate carcinoma
CVCL_0035 
[38]
Half Maximal Inhibitory Concentration (IC50) 187000 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[42]
Half Maximal Inhibitory Concentration (IC50) 18710 nM
PC-3 cells
Prostate carcinoma
CVCL_0035 
[39]
Half Maximal Inhibitory Concentration (IC50) 18740 nM
HT-29 cells
Colon adenocarcinoma
CVCL_0320 
[17]
Half Maximal Inhibitory Concentration (IC50) 1880 nM
U-937 cells
Adult acute monocytic leukemia
CVCL_0007 
[33]
Half Maximal Inhibitory Concentration (IC50) 18800 nM
PC-3 cells
Prostate carcinoma
CVCL_0035 
[27]
Half Maximal Inhibitory Concentration (IC50) 18800 nM
SMMC-7721 cells
Hepatocellular carcinoma
CVCL_0534 
[40]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 18836.49 nM
NCI-H226 cells
Pleural epithelioid mesothelioma
CVCL_1544 
[15]
Half Maximal Inhibitory Concentration (IC50) 1890 nM
RAW264.7 cells
Monocytic-macrophage leukemia
CVCL_0493 
[43]
Half Maximal Inhibitory Concentration (IC50) 18930 nM
NCI-H1299 cells (MMAE resistant)
Lung large cell carcinoma
CVCL_0060 
[17]
Half Maximal Inhibitory Concentration (IC50) 19000 nM
T-47D cells
Invasive breast carcinoma
CVCL_0553 
[18]
Half Maximal Inhibitory Concentration (IC50) 19100 nM
RAW264.7 cells
Monocytic-macrophage leukemia
CVCL_0493 
[44]
Half Maximal Inhibitory Concentration (IC50) 19470 nM
SMMC-7721 cells
Hepatocellular carcinoma
CVCL_0534 
[34]
Half Maximal Inhibitory Concentration (IC50) 19500 nM
BGC-823 cells
Stomach adenocarcinoma
CVCL_3360 
[45]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 19670 nM
K-562 cells
Chronic myelogenous leukemia
CVCL_0004 
[46]
Half Maximal Inhibitory Concentration (IC50) 19900 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[6]
Half Maximal Inhibitory Concentration (IC50) 19980 nM
PC-3 cells
Prostate carcinoma
CVCL_0035 
[17]
Half Maximal Inhibitory Concentration (IC50) 200 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[47]
Half Maximal Inhibitory Concentration (IC50) 2000 nM
PC-3 cells
Prostate carcinoma
CVCL_0035 
[25]
Half Maximal Inhibitory Concentration (IC50) 2000 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[25]
Half Maximal Inhibitory Concentration (IC50) 2000 nM
LNCaP cells
Prostate carcinoma
CVCL_0395 
[25]
Half Maximal Inhibitory Concentration (IC50) >20000 nM
SGC-7901 cells
Gastric carcinoma
CVCL_0520 
[17]
Half Maximal Inhibitory Concentration (IC50) >20000 nM
H4 cells
Neuroglioma
CVCL_1239 
[14]
Half Maximal Inhibitory Concentration (IC50) >20000 nM
H4 cells
Neuroglioma
CVCL_1239 
[14]
Half Maximal Inhibitory Concentration (IC50) >20000 nM
H4 cells
Neuroglioma
CVCL_1239 
[14]
Half Maximal Inhibitory Concentration (IC50) >20000 nM
BGC-823 cells
Stomach adenocarcinoma
CVCL_3360 
[17]
Half Maximal Inhibitory Concentration (IC50) 20000 nM
EA.hy 926 cells
Normal
CVCL_3901 
[17]
Half Maximal Inhibitory Concentration (IC50) >20000 nM
MGC-803 cells
Gastric cancer
CVCL_5334 
[17]
Half Maximal Inhibitory Concentration (IC50) >20000 nM
CT26 cells
Colon carcinoma
CVCL_7254 
[17]
Half Maximal Inhibitory Concentration (IC50) >200000 nM
H4 cells
Neuroglioma
CVCL_1239 
[14]
Half Maximal Inhibitory Concentration (IC50) 2030 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[16]
Half Maximal Inhibitory Concentration (IC50) 20300 nM
Hep-G2 cells
Hepatoblastoma
CVCL_0027 
[17]
Half Maximal Inhibitory Concentration (IC50) 20300 nM
NCI-H460 cells
Lung large cell carcinoma
CVCL_0459 
[45]
Half Maximal Inhibitory Concentration (IC50) 20500 nM
NCI-H1650 cells
Lung adenocarcinoma
CVCL_1483 
[29]
Half Maximal Inhibitory Concentration (IC50) 20700 nM
NCI-H1650 cells
Lung adenocarcinoma
CVCL_1483 
[48]
Half Maximal Inhibitory Concentration (IC50) 20730 nM
HT-29 cells
Colon adenocarcinoma
CVCL_0320 
[6]
Half Maximal Inhibitory Concentration (IC50) 20760 nM
AGS cells
Gastric adenocarcinoma
CVCL_0139 
[17]
Half Maximal Inhibitory Concentration (IC50) 2080 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[16]
Half Maximal Inhibitory Concentration (IC50) 20900 nM
PC-3 cells
Prostate carcinoma
CVCL_0035 
[17]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 2094.11 nM
RPMI-8226 cells
Plasma cell myeloma
CVCL_0014 
[15]
Half Maximal Inhibitory Concentration (IC50) 21200 nM
MGC-803 cells
Gastric cancer
CVCL_5334 
[17]
Half Maximal Inhibitory Concentration (IC50) 21300 nM
Farage cells
Normal
CVCL_0214 
[17]
Half Maximal Inhibitory Concentration (IC50) 21370 nM
HEp-2 cells
Laryngeal carcinoma
CVCL_1906 
[17]
Half Maximal Inhibitory Concentration (IC50) 21440 nM
QGY-7703 cells
Cervical carcinoma
CVCL_6715 
[34]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 21670 nM
K-562 cells
Chronic myelogenous leukemia
CVCL_0004 
[46]
Half Maximal Inhibitory Concentration (IC50) 21800 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[35]
Half Maximal Inhibitory Concentration (IC50) 220 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[42]
Half Maximal Inhibitory Concentration (IC50) 2200 nM
BV-2 cells
Normal
CVCL_0182 
[49]
Half Maximal Inhibitory Concentration (IC50) 2200 nM
RAW264.7 cells
Monocytic-macrophage leukemia
CVCL_0493 
[50]
Half Maximal Inhibitory Concentration (IC50) 22100 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[8]
Half Maximal Inhibitory Concentration (IC50) 22500 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[17]
Half Maximal Inhibitory Concentration (IC50) 22500 nM
SGC-7901 cells
Gastric carcinoma
CVCL_0520 
[17]
Half Maximal Inhibitory Concentration (IC50) 22500 nM
QGY-7703 cells
Cervical carcinoma
CVCL_6715 
[40]
Half Maximal Inhibitory Concentration (IC50) 22540 nM
THP-1 cells
Childhood acute monocytic leukemia
CVCL_0006 
[28]
Half Maximal Inhibitory Concentration (IC50) 22600 nM
N2a cells
Neuroblastoma
CVCL_0470 
[41]
Half Maximal Inhibitory Concentration (IC50) 22690 nM
L02 cells
Cervical carcinoma
CVCL_6926 
[37]
Half Maximal Inhibitory Concentration (IC50) 23000 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[51]
Half Maximal Inhibitory Concentration (IC50) 23120 nM
K-562 cells
Chronic myelogenous leukemia
CVCL_0004 
[28]
Half Maximal Inhibitory Concentration (IC50) 2330 nM
ACHN cells
Renal adenocarcinoma
CVCL_1067 
[52]
Half Maximal Inhibitory Concentration (IC50) 23400 nM
HT-29 cells
Colon adenocarcinoma
CVCL_0320 
[17]
Half Maximal Inhibitory Concentration (IC50) 23540 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[53]
Half Maximal Inhibitory Concentration (IC50) 2360 nM
BV-2 cells
Normal
CVCL_0182 
[54]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 2371.37 nM
MDA-N cells
Breast carcinoma
CVCL_1910 
[15]
Half Maximal Inhibitory Concentration (IC50) 23870 nM
L02 cells
Cervical carcinoma
CVCL_6926 
[34]
Half Maximal Inhibitory Concentration (IC50) 23910 nM
QGY-7703 cells
Cervical carcinoma
CVCL_6715 
[37]
Half Maximal Inhibitory Concentration (IC50) 2400 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[16]
Half Maximal Inhibitory Concentration (IC50) 24100 nM
NHDF cells
Normal
Undisclosed [22]
Half Maximal Inhibitory Concentration (IC50) 24180 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[55]
Half Maximal Inhibitory Concentration (IC50) 24410 nM
SGC-7901 cells
Gastric carcinoma
CVCL_0520 
[21]
Half Maximal Inhibitory Concentration (IC50) 24540 nM
MDA-MB-231 cells (5T4 overexpression)
Breast adenocarcinoma
CVCL_0062 
[31]
Half Maximal Inhibitory Concentration (IC50) 24600 nM
EA.hy 926 cells
Normal
CVCL_3901 
[56]
Half Maximal Inhibitory Concentration (IC50) 24700 nM
Lewis lung carcinoma cells
Lung carcinoma
CVCL_4358 
[48]
Half Maximal Inhibitory Concentration (IC50) 24930 nM
BT-549 cells
Breast ductal carcinoma
CVCL_1092 
[20]
Half Maximal Inhibitory Concentration (IC50) >25000 nM
Farage cells
Normal
CVCL_0214 
[57]
Half Maximal Inhibitory Concentration (IC50) >25000 nM
Caco-2 cells
Colon adenocarcinoma
CVCL_0025 
[57]
Half Maximal Inhibitory Concentration (IC50) >25000 nM
Caco-2 cells
Colon adenocarcinoma
CVCL_0025 
[57]
Half Maximal Inhibitory Concentration (IC50) >25000 nM
Caco-2 cells
Colon adenocarcinoma
CVCL_0025 
[57]
Half Maximal Inhibitory Concentration (IC50) >25000 nM
Caco-2 cells
Colon adenocarcinoma
CVCL_0025 
[57]
Half Maximal Inhibitory Concentration (IC50) >25000 nM
HT-29 cells
Colon adenocarcinoma
CVCL_0320 
[57]
Half Maximal Inhibitory Concentration (IC50) >25000 nM
HT-29 cells
Colon adenocarcinoma
CVCL_0320 
[57]
Half Maximal Inhibitory Concentration (IC50) 25000 nM
T98G cells
Glioblastoma
CVCL_0556 
[7]
Half Maximal Inhibitory Concentration (IC50) 25000 nM
Vero cells
Normal
CVCL_0059 
[16]
Half Maximal Inhibitory Concentration (IC50) 25000 nM
Sf21 cells
Normal
CVCL_0518 
[58]
Half Maximal Inhibitory Concentration (IC50) >25000 nM
EA.hy 926 cells
Normal
CVCL_3901 
[57]
Half Maximal Inhibitory Concentration (IC50) >25000 nM
EA.hy 926 cells
Normal
CVCL_3901 
[57]
Half Maximal Inhibitory Concentration (IC50) 25330 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[17]
Half Maximal Inhibitory Concentration (IC50) 25410 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[20]
Half Maximal Inhibitory Concentration (IC50) 25430 nM
PC-3 cells
Prostate carcinoma
CVCL_0035 
[19]
Half Maximal Inhibitory Concentration (IC50) 25430 nM
PC-3 cells
Prostate carcinoma
CVCL_0035 
[23]
Half Maximal Inhibitory Concentration (IC50) 25430 nM
PC-3 cells
Prostate carcinoma
CVCL_0035 
[24]
Half Maximal Inhibitory Concentration (IC50) 25430 nM
PC-3 cells
Prostate carcinoma
CVCL_0035 
[25]
Half Maximal Inhibitory Concentration (IC50) 25430 nM
PC-3 cells
Prostate carcinoma
CVCL_0035 
[26]
Half Maximal Inhibitory Concentration (IC50) 25670 nM
L02 cells
Cervical carcinoma
CVCL_6926 
[28]
Half Maximal Inhibitory Concentration (IC50) 25810 nM
U-251MG cells
Astrocytoma
CVCL_0021 
[55]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 26000 nM
NCI-H460 cells
Lung large cell carcinoma
CVCL_0459 
[46]
Half Maximal Inhibitory Concentration (IC50) 26200 nM
SGC-7901 cells
Gastric carcinoma
CVCL_0520 
[45]
Half Maximal Inhibitory Concentration (IC50) 26200 nM
MCF7R cells
Breast carcinoma
CVCL_Y493 
[59]
Half Maximal Inhibitory Concentration (IC50) 26230 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[19]
Half Maximal Inhibitory Concentration (IC50) 26230 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[23]
Half Maximal Inhibitory Concentration (IC50) 26230 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[24]
Half Maximal Inhibitory Concentration (IC50) 26230 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[25]
Half Maximal Inhibitory Concentration (IC50) 26230 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[26]
Half Maximal Inhibitory Concentration (IC50) 26500 nM
MDA-MB-231 cells (5T4 overexpression)
Breast adenocarcinoma
CVCL_0062 
[17]
Half Maximal Inhibitory Concentration (IC50) 2670 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[16]
Half Maximal Inhibitory Concentration (IC50) 26820 nM
WiDr cells
Colon adenocarcinoma
CVCL_2760 
[6]
Half Maximal Inhibitory Concentration (IC50) 2690 nM
BV-2 cells
Normal
CVCL_0182 
[60]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 2722.7 nM
LOX IMVI cells
Melanoma
CVCL_1381 
[15]
Half Maximal Inhibitory Concentration (IC50) 27230 nM
Hep-G2 cells
Hepatoblastoma
CVCL_0027 
[55]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 27300 nM
NCI-H460 cells
Lung large cell carcinoma
CVCL_0459 
[46]
Half Maximal Inhibitory Concentration (IC50) 27800 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[48]
Half Maximal Inhibitory Concentration (IC50) 27800 nM
WRL68 cells
Embryonic hepatoma
CVCL_0581 
[8]
Half Maximal Inhibitory Concentration (IC50) 27890 nM
GES1 cells
Normal
CVCL_EQ22 
[21]
Half Maximal Inhibitory Concentration (IC50) 28000 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[17]
Half Maximal Inhibitory Concentration (IC50) 28000 nM
Caco-2 cells
Colon adenocarcinoma
CVCL_0025 
[17]
Half Maximal Inhibitory Concentration (IC50) 28000 nM
HHL-5 cells
Normal
CVCL_S956 
[40]
Half Maximal Inhibitory Concentration (IC50) 28410 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[20]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 2844.46 nM
SF539 cells
Gliosarcoma
CVCL_1691 
[15]
Half Maximal Inhibitory Concentration (IC50) 28820 nM
MHCC97H cells
Hepatocellular carcinoma
CVCL_4972 
[61]
Half Maximal Inhibitory Concentration (IC50) 29000 nM
BxPC-3 CDX model cells
Pancreatic ductal adenocarcinoma
CVCL_0186 
[18]
Half Maximal Inhibitory Concentration (IC50) 29100 nM
GES1 cells
Normal
CVCL_EQ22 
[17]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 2924.15 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[15]
Half Maximal Inhibitory Concentration (IC50) 29300 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[59]
Half Maximal Inhibitory Concentration (IC50) 2940 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[16]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 2978.52 nM
MDA-MB-435 cells
Amelanotic melanoma
CVCL_0417 
[15]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 2999.16 nM
RXF 393 cells
Renal carcinoma
CVCL_1673 
[15]
Half Maximal Inhibitory Concentration (IC50) 3000 nM
BV-2 cells
Normal
CVCL_0182 
[62]
Half Maximal Inhibitory Concentration (IC50) 3000 nM
RAW264.7 cells
Monocytic-macrophage leukemia
CVCL_0493 
[63]
Half Maximal Inhibitory Concentration (IC50) 30000 nM
T-47D cells
Invasive breast carcinoma
CVCL_0553 
[64]
Half Maximal Inhibitory Concentration (IC50) 30140 nM
BT474-M1 cells
Invasive breast carcinoma
CVCL_0179 
[27]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 3019.95 nM
HCC 2998 cells
Colon adenocarcinoma
CVCL_1266 
[15]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 3026.91 nM
CCRF-CEM cells
T acute lymphoblastic leukemia
CVCL_0207 
[15]
Half Maximal Inhibitory Concentration (IC50) 30340 nM
Colon 26 cells
Colon adenocarcinoma
CVCL_0240 
[6]
Half Maximal Inhibitory Concentration (IC50) 31000 nM
J774.1 cells
Reticulum cell sarcoma
CVCL_4770 
[32]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 3126.08 nM
K-562 cells
Chronic myelogenous leukemia
CVCL_0004 
[15]
Half Maximal Inhibitory Concentration (IC50) 31390 nM
MDA-MB-231 cells (5T4 overexpression)
Breast adenocarcinoma
CVCL_0062 
[55]
Half Maximal Inhibitory Concentration (IC50) 31390 nM
MGC-803 cells
Gastric cancer
CVCL_5334 
[21]
Half Maximal Inhibitory Concentration (IC50) 31700 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[17]
Half Maximal Inhibitory Concentration (IC50) 31890 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[28]
Half Maximal Inhibitory Concentration (IC50) 32200 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[65]
Half Maximal Inhibitory Concentration (IC50) 32330 nM
L02 cells
Cervical carcinoma
CVCL_6926 
[17]
Half Maximal Inhibitory Concentration (IC50) 32390 nM
A549/CDDP cells
Lung adenocarcinoma
CVCL_C5RT 
[66]
Half Maximal Inhibitory Concentration (IC50) 32400 nM
MDA-MB-453 cells
Breast adenocarcinoma
CVCL_0418 
[27]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 3280.95 nM
SR cells
Leukemia
CVCL_1711 
[15]
Half Maximal Inhibitory Concentration (IC50) 33120 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[39]
Half Maximal Inhibitory Concentration (IC50) 33150 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[38]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 3334.26 nM
786-O cells
Renal cell carcinoma
CVCL_1051 
[15]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 3341.95 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[15]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 3500 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[67]
Half Maximal Inhibitory Concentration (IC50) 3500 nM
RAW264.7 cells
Monocytic-macrophage leukemia
CVCL_0493 
[68]
Half Maximal Inhibitory Concentration (IC50) 3560 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[16]
Half Maximal Inhibitory Concentration (IC50) 3570 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[16]
Half Maximal Inhibitory Concentration (IC50) 36000 nM
K-562 cells
Chronic myelogenous leukemia
CVCL_0004 
[17]
Half Maximal Inhibitory Concentration (IC50) 36000 nM
SK-MEL-2 cells (MEK inhibitor-resistant)
Melanoma
CVCL_0069 
[18]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 3630.78 nM
HOP-62 cells
Non-small cell lung carcinoma
CVCL_1285 
[15]
Half Maximal Inhibitory Concentration (IC50) 36770 nM
Hep-G2 cells
Hepatoblastoma
CVCL_0027 
[17]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 3784.43 nM
M14 cells
Melanoma
CVCL_1395 
[15]
Half Maximal Inhibitory Concentration (IC50) 38120 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[66]
Half Maximal Inhibitory Concentration (IC50) 3830 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[16]
Half Maximal Inhibitory Concentration (IC50) 38300 nM
Caco-2 cells
Colon adenocarcinoma
CVCL_0025 
[56]
Half Maximal Inhibitory Concentration (IC50) 39000 nM
PC-3 cells
Prostate carcinoma
CVCL_0035 
[69]
Half Maximal Inhibitory Concentration (IC50) 39420 nM
A549/CDDP cells
Lung adenocarcinoma
CVCL_C5RT 
[66]
Half Maximal Inhibitory Concentration (IC50) 4000 nM
BV-2 cells
Normal
CVCL_0182 
[70]
Half Maximal Inhibitory Concentration (IC50) >40000 nM
DLD-1 cells
Colon adenocarcinoma
CVCL_0248 
[8]
Half Maximal Inhibitory Concentration (IC50) >400000 nM
HEK293 cells
Normal
CVCL_0045 
[71]
Half Maximal Inhibitory Concentration (IC50) >400000 nM
HEK-293T cells
Normal
CVCL_0063 
[72]
Half Maximal Inhibitory Concentration (IC50) 40380 nM
MDA-MB-157 cells
Breast carcinoma
CVCL_0618 
[27]
Half Maximal Inhibitory Concentration (IC50) 40560 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[66]
Half Maximal Inhibitory Concentration (IC50) 41000 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[69]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 4120.98 nM
HCT 15 cells
Colon adenocarcinoma
CVCL_0292 
[15]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 4187.94 nM
SW620 cells
Colon adenocarcinoma
CVCL_0547 
[15]
Half Maximal Inhibitory Concentration (IC50) 42000 nM
Farage cells
Normal
CVCL_0214 
[56]
Half Maximal Inhibitory Concentration (IC50) 42830 nM
SK-BR-3 cells
Breast adenocarcinoma
CVCL_0033 
[27]
Half Maximal Inhibitory Concentration (IC50) 42890 nM
MDA-MB-468 cells
Breast adenocarcinoma
CVCL_0419 
[27]
Half Maximal Inhibitory Concentration (IC50) 42890 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[27]
Half Maximal Inhibitory Concentration (IC50) 4330 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[17]
Half Maximal Inhibitory Concentration (IC50) 43900 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[8]
Half Maximal Inhibitory Concentration (IC50) 4430 nM
Hep-G2 cells
Hepatoblastoma
CVCL_0027 
[53]
Half Maximal Inhibitory Concentration (IC50) 44710 nM
DU145 cells
Prostate carcinoma
CVCL_0105 
[31]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 4497.8 nM
SK-MEL-28 cells (BRAF inhibitor resistant)
Cutaneous melanoma
CVCL_0526 
[15]
Half Maximal Inhibitory Concentration (IC50) 4500 nM
BV-2 cells
Normal
CVCL_0182 
[73]
Half Maximal Inhibitory Concentration (IC50) 46250 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[53]
Half Maximal Inhibitory Concentration (IC50) 46760 nM
K-562 cells
Chronic myelogenous leukemia
CVCL_0004 
[55]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 4677.35 nM
MOLT-4 cells
Adult T acute lymphoblastic leukemia
CVCL_0013 
[15]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 4720.63 nM
U-251MG cells
Astrocytoma
CVCL_0021 
[15]
Half Maximal Inhibitory Concentration (IC50) 4770 nM
BV-2 cells
Normal
CVCL_0182 
[74]
Half Maximal Inhibitory Concentration (IC50) 47910 nM
T-47D cells
Invasive breast carcinoma
CVCL_0553 
[27]
Half Maximal Inhibitory Concentration (IC50) 48000 nM
Huh-7 cells
Adult hepatocellular carcinoma
CVCL_0336 
[71]
Half Maximal Inhibitory Concentration (IC50) 49400 nM
4T1 cells
Mammary carcinoma
CVCL_0125 
[69]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 4965.92 nM
BT-549 cells
Breast ductal carcinoma
CVCL_1092 
[15]
Half Maximal Inhibitory Concentration (IC50) 49850 nM
SK-OV-3 cells (FZD7 overexpression)
Ovarian serous cystadenocarcinoma
CVCL_0532 
[53]
Half Maximal Inhibitory Concentration (IC50) >50000 nM
SW620 cells
Colon adenocarcinoma
CVCL_0547 
[17]
Half Maximal Inhibitory Concentration (IC50) 50000 nM
Hep-G2 cells
Hepatoblastoma
CVCL_0027 
[10]
Half Maximal Inhibitory Concentration (IC50) 50000 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[11]
Half Maximal Inhibitory Concentration (IC50) 50000 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[10]
Half Maximal Inhibitory Concentration (IC50) 50000 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[11]
Half Maximal Inhibitory Concentration (IC50) 50000 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[3]
Half Maximal Inhibitory Concentration (IC50) >50000 nM
U-373MG ATCC cells
Astrocytoma
CVCL_2219 
[17]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 5093.31 nM
HT-29 cells
Colon adenocarcinoma
CVCL_0320 
[15]
Half Maximal Inhibitory Concentration (IC50) 51700 nM
HT-29 cells
Colon adenocarcinoma
CVCL_0320 
[56]
Half Maximal Inhibitory Concentration (IC50) 51870 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[53]
Half Maximal Inhibitory Concentration (IC50) 520 nM
BV-2 cells
Normal
CVCL_0182 
[75]
Half Maximal Inhibitory Concentration (IC50) 52300 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[17]
Half Maximal Inhibitory Concentration (IC50) 52300 nM
Hep-G2 cells
Hepatoblastoma
CVCL_0027 
[76]
Half Maximal Inhibitory Concentration (IC50) 53000 nM
PANC-1 cells
Pancreatic ductal adenocarcinoma
CVCL_0480 
[18]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 5333.35 nM
NCI-H522 cells
Non-small cell lung carcinoma
CVCL_1567 
[15]
Half Maximal Inhibitory Concentration (IC50) 5390 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[16]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 5445.03 nM
KM12 cells
Colon adenocarcinoma
CVCL_1331 
[15]
Half Maximal Inhibitory Concentration (IC50) >5510 nM
HCT 116 cells
Colon carcinoma
CVCL_0291 
[17]
Half Maximal Inhibitory Concentration (IC50) 55450 nM
Hs 578T cells
Invasive breast carcinoma
CVCL_0332 
[27]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 5597.58 nM
NCI-H23 cells
Lung adenocarcinoma
CVCL_1547 
[15]
Half Maximal Inhibitory Concentration (IC50) 58550 nM
MDA-MB-468 cells
Breast adenocarcinoma
CVCL_0419 
[27]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 58600 nM
CCD-841CoN cells
Normal
CVCL_2871 
[67]
Half Maximal Inhibitory Concentration (IC50) 6000 nM
BV-2 cells
Normal
CVCL_0182 
[77]
Half Maximal Inhibitory Concentration (IC50) 6300 nM
HL-60 cells
Adult acute myeloid leukemia
CVCL_0002 
[17]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 6486.34 nM
UACC-62 cells
Melanoma
CVCL_1780 
[15]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 6637.43 nM
OVCAR-3 cells (FZD7 overexpression)
Ovarian serous adenocarcinoma
CVCL_0465 
[15]
Half Maximal Inhibitory Concentration (IC50) 6700 nM
SK-OV-3 cells (FZD7 overexpression)
Ovarian serous cystadenocarcinoma
CVCL_0532 
[17]
Half Maximal Inhibitory Concentration (IC50) 6700 nM
MDCK cells
Normal
CVCL_0422 
[78]
Half Maximal Inhibitory Concentration (IC50) 6800 nM
A-549 cells
Lung adenocarcinoma
CVCL_0023 
[29]
Half Maximal Inhibitory Concentration (IC50) 68250 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[17]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 6839.12 nM
SNB-75 cells
Glioblastoma
CVCL_1706 
[15]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 7063.18 nM
SF268 cells
Astrocytoma
CVCL_1689 
[15]
Half Maximal Inhibitory Concentration (IC50) 7100 nM
HSC-4 cells
Cervical lymph node
CVCL_1289 
[17]
Half Maximal Inhibitory Concentration (IC50) 7150 nM
U-87MG ATCC cells
Glioblastoma
CVCL_0022 
[17]
Half Maximal Inhibitory Concentration (IC50) 7200 nM
L02 cells
Cervical carcinoma
CVCL_6926 
[29]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 7261.06 nM
NCI-ADR-RES cells
High grade ovarian serous adenocarcinoma
CVCL_1452 
[15]
Half Maximal Inhibitory Concentration (IC50) 72700 nM
Hep-G2 cells
Hepatoblastoma
CVCL_0027 
[56]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 7328.25 nM
HL-60 cells
Adult acute myeloid leukemia
CVCL_0002 
[15]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 7345.14 nM
OVCAR-8 cells
High grade ovarian serous adenocarcinoma
CVCL_1629 
[15]
Half Maximal Inhibitory Concentration (IC50) 7500 nM
Farage cells
Normal
CVCL_0214 
[57]
Half Maximal Inhibitory Concentration (IC50) 7500 nM
Bone marrow cells
Normal
Undisclosed [79]
Half Maximal Inhibitory Concentration (IC50) 75300 nM
MDA-MB-231 cells (5T4 overexpression)
Breast adenocarcinoma
CVCL_0062 
[69]
Half Maximal Inhibitory Concentration (IC50) 7700 nM
CT26 cells
Colon carcinoma
CVCL_7254 
[21]
Half Maximal Inhibitory Concentration (IC50) 7800 nM
HSC-2 cells
Oral cavity squamous cell carcinoma
CVCL_1287 
[17]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 7888.6 nM
IGROV-1 cells
Ovarian endometrioid adenocarcinoma
CVCL_1304 
[15]
Half Maximal Inhibitory Concentration (IC50) >79000 nM
H9c2 cells
Normal
CVCL_0286 
[15]
Half Maximal Inhibitory Concentration (IC50) 800 nM
RAW264.7 cells
Monocytic-macrophage leukemia
CVCL_0493 
[80]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 8035.26 nM
SF-295 cells
Glioblastoma
CVCL_1690 
[15]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 8072.35 nM
NCI-H460 cells
Lung large cell carcinoma
CVCL_0459 
[15]
Half Maximal Inhibitory Concentration (IC50) 8140 nM
PWR-1E cells
Normal
CVCL_3775 
[23]
Half Maximal Inhibitory Concentration (IC50) 8200 nM
HeLa cells
Endocervical adenocarcinoma
CVCL_0030 
[6]
Half Maximal Inhibitory Concentration (IC50) 82500 nM
NCI-H460 cells
Lung large cell carcinoma
CVCL_0459 
[65]
Half Maximal Inhibitory Concentration (IC50) 83100 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[69]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 8356.03 nM
T-47D cells
Invasive breast carcinoma
CVCL_0553 
[15]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 8413.95 nM
SN12C cells
Renal cell carcinoma
CVCL_1705 
[15]
Half Maximal Inhibitory Concentration (IC50) 8500 nM
NCI-H460 cells
Lung large cell carcinoma
CVCL_0459 
[29]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 8790.23 nM
PC-3 cells
Prostate carcinoma
CVCL_0035 
[15]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 8810.49 nM
SK-MEL-5 cells
Cutaneous melanoma
CVCL_0527 
[15]
Half Maximal Inhibitory Concentration (IC50) 8850 nM
PWR-1E cells
Normal
CVCL_3775 
[24]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 8912.51 nM
SK-OV-3 cells (FZD7 overexpression)
Ovarian serous cystadenocarcinoma
CVCL_0532 
[15]
Half Maximal Inhibitory Concentration (IC50) 9280 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[17]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 9332.54 nM
OVCAR-4 cells
Ovarian adenocarcinoma
CVCL_1627 
[15]
Half Maximal Inhibitory Concentration (IC50) 94100 nM
HEK293 cells
Normal
CVCL_0045 
[69]
Half Maximal Cell Growth Inhibitory Concentration (GI50) 9418.9 nM
SNB-19 cells
Astrocytoma
CVCL_0535 
[15]
Half Maximal Inhibitory Concentration (IC50) 9440 nM
Hep-G2 cells
Hepatoblastoma
CVCL_0027 
[17]
Half Maximal Inhibitory Concentration (IC50) 9510 nM
NIH3T3 cells
Normal
CVCL_0594 
[17]
Half Maximal Inhibitory Concentration (IC50) 9770 nM
AGS cells
Gastric adenocarcinoma
CVCL_0139 
[17]
Half Maximal Inhibitory Concentration (IC50) 9800 nM
MCF7-F (fulvestrant resistant) cells
Invasive breast carcinoma
CVCL_0031 
[22]
Each Antibody-drug Conjugate Related to This Payload
References
Ref 1 Synthesis of novel 4-Boc-piperidone chalcones and evaluation of their cytotoxic activity against highly-metastatic cancer cells. Bioorg Med Chem Lett. 2020 Jan 1;30(1):126760. doi: 10.1016/j.bmcl.2019.126760. Epub 2019 Oct 28.
Ref 2 Recent progress in the structural modification and pharmacological activities of ligustrazine derivatives. Eur J Med Chem. 2018 Mar 10;147:150-162. doi: 10.1016/j.ejmech.2018.01.097. Epub 2018 Feb 5.
Ref 3 Synthesis and biological evaluation of curcumin derivatives modified with -amino boronic acid as proteasome inhibitors. Bioorg Med Chem Lett. 2018 Aug 1;28(14):2459-2464. doi: 10.1016/j.bmcl.2018.06.004. Epub 2018 Jun 2.
Ref 4 Isoxazole-tethered diarylheptanoid analogs: Discovery of a new drug-like PAR2 antagonist. Bioorg Med Chem Lett. 2018 Jul 15;28(13):2285-2288. doi: 10.1016/j.bmcl.2018.05.032. Epub 2018 May 21.
Ref 5 Another look at phenolic compounds in cancer therapy the effect of polyphenols on ubiquitin-proteasome system. Eur J Med Chem. 2019 Apr 1;167:291-311. doi: 10.1016/j.ejmech.2019.01.044. Epub 2019 Jan 30.
Ref 6 Recent advances of analogues of curcumin for treatment of cancer. Eur J Med Chem. 2019 Oct 15;180:524-535. doi: 10.1016/j.ejmech.2019.07.034. Epub 2019 Jul 10.
Ref 7 Gambogic acid induces apoptotic cell death in T98G glioma cells. Bioorg Med Chem Lett. 2016 Feb 1;26(3):1097-1101. doi: 10.1016/j.bmcl.2015.11.043. Epub 2015 Nov 14.
Ref 8 Antiproliferative efficacy of curcumin mimics through microtubule destabilization. Eur J Med Chem. 2018 May 10;151:51-61. doi: 10.1016/j.ejmech.2018.03.063. Epub 2018 Mar 26.
Ref 9 Synthesis, biological evaluation and QSAR studies of diarylpentanoid analogues as potential nitric oxide inhibitors. Medchemcomm. 2015;6(6):1069-1080.
Ref 10 Structure activity relationship, cytotoxicity and evaluation of antioxidant activity of curcumin derivatives. Bioorg Med Chem Lett. 2016 Feb 15;26(4):1342-7. doi: 10.1016/j.bmcl.2015.12.013. Epub 2015 Dec 7.
Ref 11 Design, structure activity relationship, cytotoxicity and evaluation of antioxidant activity of curcumin derivatives/analogues. Eur J Med Chem. 2016 Oct 4;121:510-516. doi: 10.1016/j.ejmech.2016.05.037. Epub 2016 May 21.
Ref 12 Resveratrol-Related Polymethoxystilbene Glycosides: Synthesis, Antiproliferative Activity, and Glycosidase Inhibition. J Nat Prod. 2015 Nov 25;78(11):2675-83. doi: 10.1021/acs.jnatprod.5b00619. Epub 2015 Nov 5.
Ref 13 X-ray crystal structures, density functional theory and docking on deacetylase enzyme for antiproliferative activity of hispolon derivatives on HCT116 colon cancer. Bioorg Med Chem. 2019 Sep 1;27(17):3805-3812. doi: 10.1016/j.bmc.2019.07.008. Epub 2019 Jul 5.
Ref 14 Amyloid- and tau aggregation dual-inhibitors: A synthetic and structure-activity relationship focused review. Eur J Med Chem. 2021 Mar 15;214:113209. doi: 10.1016/j.ejmech.2021.113209. Epub 2021 Jan 25.
Ref 15 PubChem BioAssay data set.
Ref 16 Influence of side-chain changes on histone deacetylase inhibitory and cytotoxicity activities of curcuminoid derivatives. Bioorg Med Chem Lett. 2020 Jun 1;30(11):127171. doi: 10.1016/j.bmcl.2020.127171. Epub 2020 Apr 4.
Ref 17 Developments in the anticancer activity of structurally modified curcumin: An up-to-date review. Eur J Med Chem. 2019 Sep 1;177:76-104. doi: 10.1016/j.ejmech.2019.04.058. Epub 2019 May 14.
Ref 18 Polyphenolic Phytochemicals in Cancer Prevention and Therapy: Bioavailability versus Bioefficacy. J Med Chem. 2017 Dec 14;60(23):9413-9436. doi: 10.1021/acs.jmedchem.6b01026. Epub 2017 Jul 11.
Ref 19 Synthesis and evaluation of 1,7-diheteroarylhepta-1,4,6-trien-3-ones as curcumin-based anticancer agents. Eur J Med Chem. 2016 Mar 3;110:164-80. doi: 10.1016/j.ejmech.2016.01.017. Epub 2016 Jan 21.
Ref 20 Synthesis and biological evaluation of curcumin inspired indole analogues as tubulin polymerization inhibitors. Eur J Med Chem. 2017 Feb 15;127:100-114. doi: 10.1016/j.ejmech.2016.12.043. Epub 2016 Dec 23.
Ref 21 Design, synthesis, and anticancer evaluation of long-chain alkoxylated mono-carbonyl analogues of curcumin. Eur J Med Chem. 2015 Oct 20;103:44-55. doi: 10.1016/j.ejmech.2015.08.036. Epub 2015 Aug 19.
Ref 22 Asymmetrical meta-methoxylated diarylpentanoids: Rational design, synthesis and anti-cancer evaluation in-vitro. Eur J Med Chem. 2018 Sep 5;157:716-728. doi: 10.1016/j.ejmech.2018.08.039. Epub 2018 Aug 16.
Ref 23 Structure-activity relationship studies of 1,7-diheteroarylhepta-1,4,6-trien-3-ones with two different terminal rings in prostate epithelial cell models. Eur J Med Chem. 2017 Jun 16;133:208-226. doi: 10.1016/j.ejmech.2017.03.067. Epub 2017 Mar 29.
Ref 24 Asymmetric 1,5-diarylpenta-1,4-dien-3-ones: Antiproliferative activity in prostate epithelial cell models and pharmacokinetic studies. Eur J Med Chem. 2017 Sep 8;137:263-279. doi: 10.1016/j.ejmech.2017.05.062. Epub 2017 Jun 3.
Ref 25 Optimization of diarylpentadienones as chemotherapeutics for prostate cancer. Bioorg Med Chem. 2018 Sep 1;26(16):4751-4760. doi: 10.1016/j.bmc.2018.08.018. Epub 2018 Aug 13.
Ref 26 Design, synthesis, and biological evaluation of 1,9-diheteroarylnona-1,3,6,8-tetraen-5-ones as a new class of anti-prostate cancer agents. Bioorg Med Chem. 2016 Oct 1;24(19):4692-4700. doi: 10.1016/j.bmc.2016.08.006. Epub 2016 Aug 6.
Ref 27 New bis(hydroxymethyl) alkanoate curcuminoid derivatives exhibit activity against triple-negative breast cancer in?vitro and in?vivo. Eur J Med Chem. 2017 May 5;131:141-151. doi: 10.1016/j.ejmech.2017.03.006. Epub 2017 Mar 8.
Ref 28 Novel dissymmetric 3,5-bis(arylidene)-4-piperidones as potential antitumor agents with biological evaluation in?vitro and in?vivo. Eur J Med Chem. 2018 Mar 10;147:21-33. doi: 10.1016/j.ejmech.2018.01.088. Epub 2018 Jan 31.
Ref 29 Design, synthesis, anti-lung cancer activity, and chemosensitization of tumor-selective MCACs based on ROS-mediated JNK pathway activation and NF-B pathway inhibition. Eur J Med Chem. 2018 May 10;151:508-519. doi: 10.1016/j.ejmech.2018.03.051. Epub 2018 Apr 6.
Ref 30 Spirobisnaphthalenes and lactones from the seeds of Strychnos angustiflora with potential anti-inflammatory activity. Bioorg Med Chem Lett. 2016 Oct 1;26(19):4832-4836. doi: 10.1016/j.bmcl.2016.08.019. Epub 2016 Aug 9.
Ref 31 4-Carbonyl-2,6-dibenzylidenecyclohexanone derivatives as small molecule inhibitors of STAT3 signaling pathway. Bioorg Med Chem. 2016 Dec 1;24(23):6174-6182. doi: 10.1016/j.bmc.2016.09.070. Epub 2016 Sep 30.
Ref 32 Focus on PAINS: false friends in the quest for selective anti-protozoal lead structures from Nature?. Medchemcomm. 2016;7(2):214-223.
Ref 33 Synthesis of unsymmetrical monocarbonyl curcumin analogues with potent inhibition on prostaglandin E2 production in LPS-induced murine and human macrophages cell lines. Bioorg Med Chem Lett. 2016 May 15;26(10):2531-2538. doi: 10.1016/j.bmcl.2016.03.092. Epub 2016 Mar 26.
Ref 34 N-phenylsulfonyl-3,5-bis(arylidene)-4-piperidone derivatives as activation NF-B inhibitors in hepatic carcinoma cell lines. Eur J Med Chem. 2018 Jul 15;155:531-544. doi: 10.1016/j.ejmech.2018.06.027. Epub 2018 Jun 12.
Ref 35 Triazole-curcuminoids: A new class of derivatives for 'tuning' curcumin bioactivities?. Bioorg Med Chem. 2016 Jan 15;24(2):140-52. doi: 10.1016/j.bmc.2015.11.044. Epub 2015 Nov 30.
Ref 36 Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators. Eur J Med Chem. 2022 Jul 5;237:114346. doi: 10.1016/j.ejmech.2022.114346. Epub 2022 Apr 6.
Ref 37 Dissymmetric pyridyl-substituted 3,5-bis(arylidene)-4-piperidones as anti-hepatoma agents by inhibiting NF-B pathway activation. Eur J Med Chem. 2019 Apr 1;167:187-199. doi: 10.1016/j.ejmech.2019.02.020. Epub 2019 Feb 7.
Ref 38 Curcumin inspired 2-chloro/phenoxy quinoline analogues: Synthesis and biological evaluation as potential anticancer agents. Bioorg Med Chem Lett. 2018 Mar 1;28(5):892-898. doi: 10.1016/j.bmcl.2018.01.070. Epub 2018 Feb 2.
Ref 39 Synthesis and biological evaluation of curcumin inspired imidazo[1,2-a]pyridine analogues as tubulin polymerization inhibitors. Eur J Med Chem. 2018 Jan 1;143:216-231. doi: 10.1016/j.ejmech.2017.11.010. Epub 2017 Nov 5.
Ref 40 Discovery of anti-hepatoma agents from 1,4,5,6,7,8-hexahydropyrido[4,3-d]pyrimidine by inhibiting PI3K/AKT/NF-B pathway activation. Eur J Med Chem. 2021 Dec 5;225:113796. doi: 10.1016/j.ejmech.2021.113796. Epub 2021 Aug 21.
Ref 41 Development of curcumin-based amyloid aggregation inhibitors for Alzheimer's disease using the SAR matrix approach. Bioorg Med Chem. 2021 Sep 15;46:116357. doi: 10.1016/j.bmc.2021.116357. Epub 2021 Aug 8.
Ref 42 Can Small Chemical Modifications of Natural Pan-inhibitors Modulate the Biological Selectivity? The Case of Curcumin Prenylated Derivatives Acting as HDAC or mPGES-1 Inhibitors. J Nat Prod. 2015 Dec 24;78(12):2867-79. doi: 10.1021/acs.jnatprod.5b00700. Epub 2015 Nov 20.
Ref 43 Discovery of diarylheptanoids that activate 7 nAchR-JAK2-STAT3 signaling in macrophages with anti-inflammatory activity in vitro and in vivo. Bioorg Med Chem. 2022 Jul 15;66:116811. doi: 10.1016/j.bmc.2022.116811. Epub 2022 May 10.
Ref 44 Bioactive Constituents of Glycyrrhiza uralensis (Licorice): Discovery of the Effective Components of a Traditional Herbal Medicine. J Nat Prod. 2016 Feb 26;79(2):281-92. doi: 10.1021/acs.jnatprod.5b00877. Epub 2016 Feb 3.
Ref 45 Design, synthesis and QSAR study of novel isatin analogues inspired Michael acceptor as potential anticancer compounds. Eur J Med Chem. 2018 Jan 20;144:493-503. doi: 10.1016/j.ejmech.2017.12.043. Epub 2017 Dec 18.
Ref 46 A novel curcumin derivative which inhibits P-glycoprotein, arrests cell cycle and induces apoptosis in multidrug resistance cells. Bioorg Med Chem. 2017 Jan 15;25(2):581-596. doi: 10.1016/j.bmc.2016.11.023. Epub 2016 Nov 19.
Ref 47 Targeting microsomal prostaglandin E-2 synthase-1 (mPGES-1): the development of inhibitors as an alternative to non-steroidal anti-inflammatory drugs (NSAIDs). Medchemcomm. 2015;6(12):2081-2123.
Ref 48 Design, synthesis, and evaluation of asymmetric EF24 analogues as potential anti-cancer agents for lung cancer. Eur J Med Chem. 2017 Jan 5;125:1321-1331. doi: 10.1016/j.ejmech.2016.10.027. Epub 2016 Oct 15.
Ref 49 A Novel Parkinson's Disease Drug Candidate with Potent Anti-neuroinflammatory Effects through the Src Signaling Pathway. J Med Chem. 2016 Oct 13;59(19):9062-9079. doi: 10.1021/acs.jmedchem.6b00976. Epub 2016 Sep 27.
Ref 50 Anti-inflammatory Dimeric Tetrahydroxanthones from an Endophytic Muyocopron laterale. J Nat Prod. 2022 Jan 28;85(1):148-161. doi: 10.1021/acs.jnatprod.1c00878. Epub 2022 Jan 14.
Ref 51 From bench (laboratory) to bed (hospital/home): How to explore effective natural and synthetic PAK1-blockers/longevity-promoters for cancer therapy. Eur J Med Chem. 2017 Dec 15;142:229-243. doi: 10.1016/j.ejmech.2017.07.043. Epub 2017 Aug 9.
Ref 52 Water-soluble prodrugs of paclitaxel containing self-immolative disulfide linkers. Bioorg Med Chem Lett. 2015 Jan 1;25(1):122-7. doi: 10.1016/j.bmcl.2014.10.088. Epub 2014 Nov 12.
Ref 53 Synthesis and evaluation of anticancer and antiobesity activity of 1-ethoxy carbonyl-3,5-bis (3'-indolyl methylene)-4-pyperidone analogs. Bioorg Med Chem Lett. 2016 Mar 15;26(6):1633-1638. doi: 10.1016/j.bmcl.2016.01.073. Epub 2016 Jan 28.
Ref 54 Polycycloiridals with a Cyclopentane Ring from Iris tectorum. J Nat Prod. 2017 Jan 27;80(1):156-161. doi: 10.1021/acs.jnatprod.6b00796. Epub 2016 Dec 29.
Ref 55 A novel selective mitochondrial-targeted curcumin analog with remarkable cytotoxicity in glioma cells. Eur J Med Chem. 2021 Oct 5;221:113528. doi: 10.1016/j.ejmech.2021.113528. Epub 2021 May 12.
Ref 56 Synthesis and biological assessment of novel N-(hydroxy/methoxy)alkyl -enaminone curcuminoids. Bioorg Med Chem Lett. 2016 Dec 1;26(23):5650-5656. doi: 10.1016/j.bmcl.2016.10.068. Epub 2016 Oct 24.
Ref 57 Synthesis of novel curcuminoids accommodating a central -enaminone motif and their impact on cell growth and oxidative stress. Eur J Med Chem. 2016 Nov 10;123:727-736. doi: 10.1016/j.ejmech.2016.07.017. Epub 2016 Jul 11.
Ref 58 Discovery of Highly Potent, Selective, and Orally Efficacious p300/CBP Histone Acetyltransferases Inhibitors. J Med Chem. 2020 Feb 13;63(3):1337-1360. doi: 10.1021/acs.jmedchem.9b01721. Epub 2020 Jan 28.
Ref 59 Isoxazole derivatives as anticancer agent: A review on synthetic strategies, mechanism of action and SAR studies. Eur J Med Chem. 2021 Oct 5;221:113511. doi: 10.1016/j.ejmech.2021.113511. Epub 2021 May 6.
Ref 60 Anti-Epstein-Barr Viral Agents from the Medicinal Herb-Derived Fungus Alternaria alstroemeriae Km2286. J Nat Prod. 2022 Nov 25;85(11):2667-2674. doi: 10.1021/acs.jnatprod.2c00783. Epub 2022 Nov 8.
Ref 61 Structure modification and biological evaluation of indole-chalcone derivatives as anti-tumor agents through dual targeting tubulin and TrxR. Eur J Med Chem. 2022 Jan 5;227:113897. doi: 10.1016/j.ejmech.2021.113897. Epub 2021 Oct 5.
Ref 62 Polyketides with Anti-neuroinflammatory Activity from Theissenia cinerea. J Nat Prod. 2021 Jul 23;84(7):1898-1903. doi: 10.1021/acs.jnatprod.0c01307. Epub 2021 Jun 29.
Ref 63 Beta-Glucuronidase Catalyzes Deconjugation and Activation of Curcumin-Glucuronide in Bone. J Nat Prod. 2019 Mar 22;82(3):500-509. doi: 10.1021/acs.jnatprod.8b00873. Epub 2019 Feb 22.
Ref 64 Modulatory effects of silibinin in various cell signaling pathways against liver disorders and cancer - A comprehensive review. Eur J Med Chem. 2016 Nov 10;123:577-595. doi: 10.1016/j.ejmech.2016.07.070. Epub 2016 Jul 29.
Ref 65 Synthesis and anticancer activity of novel curcumin-quinolone hybrids. Bioorg Med Chem Lett. 2015 Sep 1;25(17):3601-5. doi: 10.1016/j.bmcl.2015.06.068. Epub 2015 Jun 26.
Ref 66 Discovery of New Monocarbonyl Ligustrazine-Curcumin Hybrids for Intervention of Drug-Sensitive and Drug-Resistant Lung Cancer. J Med Chem. 2016 Mar 10;59(5):1747-60. doi: 10.1021/acs.jmedchem.5b01203. Epub 2016 Feb 26.
Ref 67 3,5-Bis(3-dimethylaminomethyl-4-hydroxybenzylidene)-4-piperidone and related compounds induce glutathione oxidation and mitochondria-mediated cell death in HCT-116 colon cancer cells. Bioorg Med Chem Lett. 2017 Aug 15;27(16):3669-3673. doi: 10.1016/j.bmcl.2017.07.018. Epub 2017 Jul 5.
Ref 68 Sesquiterpene Lactones from Sigesbeckia glabrescens Possessing Potent Anti-inflammatory Activity by Directly Binding to IKK/. J Nat Prod. 2021 Nov 26;84(11):2808-2821. doi: 10.1021/acs.jnatprod.1c00416. Epub 2021 Nov 2.
Ref 69 Synthesis and biological evaluation of some novel triazole hybrids of curcumin mimics and their selective anticancer activity against breast and prostate cancer cell lines. Bioorg Med Chem Lett. 2016 Sep 1;26(17):4223-32. doi: 10.1016/j.bmcl.2016.07.053. Epub 2016 Jul 25.
Ref 70 Sesquiterpenes from the Endophyte Glomerella cingulata. J Nat Prod. 2017 Oct 27;80(10):2609-2614. doi: 10.1021/acs.jnatprod.7b00054. Epub 2017 Oct 16.
Ref 71 Structure guided design of potential inhibitors of human calcium-calmodulin dependent protein kinase IV containing pyrimidine scaffold. Bioorg Med Chem Lett. 2016 Feb 1;26(3):782-788. doi: 10.1016/j.bmcl.2015.12.098. Epub 2015 Dec 30.
Ref 72 Synthesis, estrogen receptor binding affinity and molecular docking of pyrimidine-piperazine-chromene and -quinoline conjugates. Bioorg Med Chem Lett. 2017 Sep 15;27(18):4493-4499. doi: 10.1016/j.bmcl.2017.07.077. Epub 2017 Jul 29.
Ref 73 Bioactive Constituents from the Termite Nest-Derived Medicinal Fungus Xylaria nigripes. J Nat Prod. 2017 Jan 27;80(1):38-44. doi: 10.1021/acs.jnatprod.6b00249. Epub 2017 Jan 5.
Ref 74 Bioactive Sesquiterpenoid and Polyacetylene Glycosides from Atractylodes lancea. J Nat Prod. 2016 Jun 24;79(6):1567-75. doi: 10.1021/acs.jnatprod.6b00066. Epub 2016 May 26.
Ref 75 Bioactive Iridoid Glycosides from the Whole Plants of Rehmannia chingii. J Nat Prod. 2016 Feb 26;79(2):428-33. doi: 10.1021/acs.jnatprod.5b01126. Epub 2016 Feb 9.
Ref 76 3,3'-OH curcumin causes apoptosis in HepG2 cells through ROS-mediated pathway. Eur J Med Chem. 2016 Apr 13;112:157-163. doi: 10.1016/j.ejmech.2016.02.019. Epub 2016 Feb 9.
Ref 77 Hirsutane-Type Sesquiterpenes with Inhibitory Activity of Microglial Nitric Oxide Production from the Red Alga-Derived Fungus Chondrostereum sp. NTOU4196. J Nat Prod. 2017 May 26;80(5):1615-1622. doi: 10.1021/acs.jnatprod.7b00196. Epub 2017 May 17.
Ref 78 Synthesis of novel pentacyclic triterpene-Neu5Ac2en derivatives and investigation of their in vitro anti-influenza entry activity. Medchemcomm. 2017 Jun 2;8(7):1531-1541. doi: 10.1039/c7md00245a. eCollection 2017 Jul 1.
Ref 79 Cyclolinopeptides, cyclic peptides from flaxseed with osteoclast differentiation inhibitory activity. Bioorg Med Chem Lett. 2016 Apr 1;26(7):1760-1. doi: 10.1016/j.bmcl.2016.02.040. Epub 2016 Feb 16.
Ref 80 Design and synthesis of novel 1,3,5-triphenyl pyrazolines as potential anti-inflammatory agents through allosteric inhibition of protein kinase Czeta (PKC). Medchemcomm. 2018 May 7;9(6):1076-1082. doi: 10.1039/c8md00100f. eCollection 2018 Jun 1.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.